Efficacy and safety comparison of roxadustat versus recombinant human erythropoietin combined with intravenous iron for renal anemia in patients undergoing maintenance hemodialysis
- VernacularTitle:罗沙司他或重组人促红素联合静脉用铁剂治疗维持性血液透析合并肾性贫血的疗效与安全性比较
- Author:
Jiang LIU
1
;
Wenfei DING
1
;
Li WEN
1
Author Information
1. Dept. of Nephrology，the Affiliated Hospital of Southwest Medical University，Sichuan Luzhou 646000，China
- Publication Type:Journal Article
- Keywords:
roxadustat;
recombinant human erythropoietin;
maintenance hemodialysis;
renal anemia;
end-stage renal disease
- From:
China Pharmacy
2025;36(19):2422-2427
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy and safety of roxadustat versus recombinant human erythropoietin （rHuEPO）， each combined with intravenous iron supplementation， in the treatment of renal anemia （RA） in patients undergoing maintenance hemodialysis （MHD）. METHODS A retrospective analysis was conducted on the medical records of 152 patients diagnosed with RA and receiving MHD at the Affiliated Hospital of Southwest Medical University between January 2022 and June 2024. According to the treatment regimen， patients were divided into observation group （n＝72） and control group （n＝80）. Both groups of patients received MHD and intravenous iron therapy， with the observation group additionally receiving roxadustat and the control group receiving rHuEPO， both for a treatment duration of 12 weeks. Changes in anemia indicators， iron metabolism parameters， inflammatory markers， cardiac function parameters， quality of life scores before and after therapy， and adverse events during treatment were compared between the two groups. RESULTS After 12 weeks of treatment， both groups showed significant increase in hemoglobin， red blood cell count， hematocrit， serum iron， transferrin， total iron binding capacity， transferrin saturation， left ventricular ejection fraction， E/A ratio， cardiac output， 36-Item Short Form Health Survey score， and Kidney Disease Quality of Life Short Form score compared to baseline （P＜0.05）. Conversely， the levels of ferritin， C-reactive protein， interleukin-6， tumor necrosis factor-α， brain natriuretic peptide， and N-terminal pro-B-type natriuretic peptide were significantly reduced （P＜0.05）. The improvements in the observation group were significantly greater than those in the control group （P＜ 0.05）. Moreover， the incidence of adverse events was significantly lower in the observation group compared to the control group （P＜0.05）. CONCLUSIONS Compared to rHuEPO combined with intravenous iron supplementation， roxadustat combined with intravenous iron supplementation is more effective in improving anemia， iron metabolism， inflammatory status， cardiac function， and quality of life in patients with RA undergoing MHD. Additionally， it demonstrates a better safety profile.
